Institutional investors purchased a net $1.1 million shares of ILMN during the quarter ended March 2017 and now own 96.01% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CREDIT SUISSE AG Bought 42.2 Thousand shares of Illumina Inc